Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 HitGen, Nested Therapeutics Ink Research Service Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

HitGen, Nested Therapeutics Ink Research Service Agreement

HitGen will utilize its DNA-encoded library technology platform for the design, synthesis, and screening of DELs.

By: Anthony Vecchione

HitGen Inc., a drug discovery research company, has entered into a research service agreement with Nested Therapeutics, Inc., a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis, and screening of DELs, to identify hits against targets of interest to Nested.

HitGen is involved in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.

“We look forward to working with the research teams at Nested to generate novel starting points for their research programs to help address the unmet needs of patients with cancer,” said Jin Li, Chairman of the Board and CEO of HitGen Inc. “As one of HitGen’s four core technology platforms, our world-leading DEL platform is an efficient ‘engine’ to advance drug discovery and has enabled hit identification and lead generation for many innovative discovery programs by our customers and partners. We look forward to delivering useful outcome for Nested’s research programs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics